Consumer medicine information

Noralin

Noradrenaline (norepinephrine)

BRAND INFORMATION

Brand name

Noralin

Active ingredient

Noradrenaline (norepinephrine)

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Noralin.

What is in this leaflet

Please read this leaflet carefully before you are given Noralin.

This leaflet answers some common questions about Noralin. It does not contain all the available information. The most up-to-date Consumer Medicine Information can be downloaded from www.ebs.tga.gov.au.

Reading this leaflet does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of giving you Noralin against the benefits this medicine is expected to have for you.

If you have any concerns about being given this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may want to read it again.

What Noralin is used for

Noralin contains noradrenaline (norepinephrine) acid tartrate monohydrate. It belongs to a group of medicines called sympathomimetic amines. It works by making the heartbeat more forcefully and constricting blood vessels. This results in a higher blood pressure and greater blood flow to the heart and other organs of the body.

Noralin is given in emergency situations as a result of medical conditions which cause a dramatic drop in blood pressure. Such situations/conditions could be:

  • associated with surgical procedures
  • infections caused by poliovirus
  • a heart attack
  • infection in the blood
  • severe reaction to a medicine
  • severe reaction to a blood transfusion
  • allergic reactions.

Noralin is used to restore blood pressure back to normal. It is given only by a doctor or nurse, usually in hospital.

Your doctor may have prescribed this medicine for another reason.

Ask your doctor if you have any questions about why it has been prescribed for you.

Noralin is only available with a doctor's prescription.

There is no evidence that Noralin is addictive.

Before you are given Noralin

Noralin is not suitable for everyone.

When you must not be given it

You must not be given Noralin if you have:

  • low blood pressure due to low blood volume
  • blood clots in certain vessels.

If given in these cases, it can further reduce blood supply to important organs.

You must not be given Noralin if you are allergic to any medicine containing noradrenaline (norepinephrine), or any other similar medicines such as adrenaline, phenylephrine, pseudoephedrine, or any of the ingredients listed at the end of this leaflet.

Noralin must not be used after the expiry date printed on the pack, or if the packaging is torn or shows signs of tampering. The solution must be clear before use.

If you are not sure whether you should be given this medicine, talk to your doctor.

Before you are given it

Tell your doctor or pharmacist if you have allergies to any other medicines, or any other substances, such as foods, preservatives or dyes.

Tell your doctor if you have or have had an overactive thyroid gland.

Tell your doctor or pharmacist if you are pregnant or breastfeeding. Noralin may be given to pregnant women and women who are breastfeeding, but your doctor must be told if you are pregnant or breastfeeding. Your doctor will discuss the possible risks and benefits of you being given Noralin during pregnancy and breastfeeding.

Tell your doctor or pharmacist if you are over 65 years old Elderly persons may be more sensitive to the effects of the medicine.

If you have not told your doctor about any of the above, tell them before you are given Noralin.

Tell your doctor if you have any medical conditions before being given Noralin.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and Noralin may interfere with each other. These include:

  • antidepressants including moclobemide, imipramine and amitriptyline.

The above medicines may be affected by Noralin, or may affect how well it works. You may need different amounts of Noralin, or you may need to use different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while being given Noralin.

How Noralin is given

How it will be given

Noralin is ready-to use solution and should NOT be diluted. It will be given by slow intravenous infusion into a large vein. This medicine must only be given by a doctor or a nurse.

How much will be given

Your doctor will decide how many infusions you need, and how often you should receive them. The need for more doses will depend on how the medicine is affecting your blood pressure.

How long it will be given for

This medicine will be given until blood pressure and blood circulation to all organs is back to normal and remains normal even when the medicine is no longer given.

While you are being given Noralin

Things you must do

If you are about to be started on any new medicine, tell your doctor and pharmacist that you are being given Noralin. Likewise, tell any other doctors, dentists and pharmacists who are treating you that you are being given this medicine.

Tell your doctor immediately if you develop a rash or other symptoms of an allergic reaction.

These symptoms may be:

  • shortness of breath, wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

In case of overdose

If you are given too much

As Noralin is given to you in hospital under the supervision of your doctor, it is very unlikely that you will receive an overdose.

Symptoms of an overdose may include headache, dizziness, sensitivity to light, slow heartbeat, chest pain, sweating and pale skin, vomiting, or trouble breathing.

Immediately tell your doctor or nurse if you think that you or anyone else may have been given too much Noralin. They have information on how to recognise and treat an overdose.

Side effects

Tell your doctor as soon as possible if you do not feel well while you are being given Noralin.

Like all medicines, Noralin may occasionally cause side effects in some people. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or nurse if you notice any of the following:

  • skin and tissue damage close to the site of injection
  • anxiety, sleeplessness, psychotic state, feeling of confusion, agitation, weakness and shaking
  • headache
  • signs of change in blood pressure such as dizziness
  • tingling or numbness in the feet
  • coldness, numbness or discolouration of your limbs
  • acute glaucoma
  • increased saliva
  • passing less urine than normal or no urine, pain when passing urine.

If any of the following happen, tell your doctor or a nurse immediately:

  • serious allergic reaction (symptoms of an allergic reaction may include shortness of breath, wheezing or difficulty breathing, swelling of the face, lips, tongue or other parts of the body, rash, itching or hives on the skin)
  • breathing difficulties
  • fast, slow or irregular heartbeat, chest pain, palpitations
  • severe high blood pressure (symptoms may include violent headaches, extreme light sensitivity, intense sweating, nausea, vomiting, pale skin, or pain behind the breastbone).

These are very serious side effects; you may need urgent medical attention.

If you are over 65 years of age, you may have an increased chance of getting side effects.

Tell your doctor if you notice anything else that is making you feel unwell. Other side effects not listed above may also occur in some patients.

Do not be alarmed by this list of possible side effects. You may not experience any of them.

After being given Noralin

Storage

Noralin will be stored in the pharmacy or on the ward under the recommended storage conditions.

It must be kept in a cool dry place, protected from light, where the temperature stays below 25°C. Do not refrigerate or freeze.

Disposal

Any Noralin which has passed its expiry date, or is left in the container after use, will be disposed of in a safe manner by your doctor, nurse or pharmacist.

Product description

What it looks like

Noralin is a clear sterile solution for intravenous infusion.

It is available in 50 mL vials in the following strengths: 3 mg/50 mL, 5 mg/50 mL, 6 mg/50 mL and 10 mg/ 50 mL. A box contains 1 vial.

Each 3 mg/50 mL vial contains noradrenaline (norepinephrine) 0.06 mg in 1 mL, present as 0.12 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.

Each 5 mg/50 mL vial contains noradrenaline (norepinephrine) 0.1 mg in 1 mL, present as 0.2 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.

Each 6 mg/50 mL vial contains noradrenaline (norepinephrine) 0.12 mg in 1 mL, present as 0.24 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.

Each 10/50 mL vial contains noradrenaline (norepinephrine) 0.2 mg in 1 mL, present as 0.4 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.

Not all presentations may be available.

Ingredients

Active ingredient:

  • noradrenaline (norepinephrine)

Inactive ingredients:

  • sodium chloride
  • hydrochloric acid
  • water for injections.

Noralin is sulfite free and does not contain any preservatives.

Sponsor details

Boucher & Muir Pty Ltd
Level 9, 76 Berry Street
North Sydney NSW 2060

Distributed in New Zealand by:

BNM Group
39 Anzac Road
Browns Bay
Auckland 0753

3 mg/50 mL: AUST R 316838

5 mg/50 mL: AUST R 316839

6 mg/50 mL: AUST R 316840

10 mg/50 mL: AUST R 316841

Date of preparation

This leaflet was prepared on 15 August 2022.

Published by MIMS October 2022

BRAND INFORMATION

Brand name

Noralin

Active ingredient

Noradrenaline (norepinephrine)

Schedule

S4

 

1 Name of Medicine

Noradrenaline (norepinephrine) (as acid tartrate monohydrate).

2 Qualitative and Quantitative Composition

Noralin is available in the following strengths:
Noradrenaline (norepinephrine) (as acid tartrate monohydrate) 3 mg/50 mL.
Noradrenaline (norepinephrine) (as acid tartrate monohydrate) 5 mg/50 mL.
Noradrenaline (norepinephrine) (as acid tartrate monohydrate) 6 mg/50 mL.
Noradrenaline (norepinephrine) (as acid tartrate monohydrate) 10 mg/50 mL.
Each 3 mg/50 mL vial contains noradrenaline (norepinephrine) 0.06 mg in 1 mL, present as 0.12 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.
Each 5 mg/50 mL vial contains noradrenaline (norepinephrine) 0.1 mg in 1 mL, present as 0.2 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.
Each 6 mg/50 mL vial contains noradrenaline (norepinephrine) 0.12 mg in 1 mL, present as 0.24 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.
Each 10 mg/50 mL vial contains noradrenaline (norepinephrine) 0.2 mg in 1 mL, present as 0.4 mg of noradrenaline (norepinephrine) acid tartrate monohydrate in 1 mL.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Noralin is a sterile, clear colourless solution for intravenous infusion available in vials.

4 Clinical Particulars

4.1 Therapeutic Indications

For the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion and drug reactions).
As an adjunct in the treatment of cardiac arrest. To restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means.

4.2 Dose and Method of Administration

Noralin should only be administered by healthcare professionals familiar with its use.
Noralin is a ready-to-use solution for intravenous infusion. The solution should not be diluted before use.
An infusion of Noralin should be given into a large vein (see Section 4.4 Special Warnings and Precautions for Use). Whole blood or plasma, if indicated to increase blood volume, should be administered separately.
Noralin contains no antimicrobial preservative. It is for single use in one patient only. Discard any residue. Discoloured solutions or those containing a precipitate should not be used. Avoid contact with iron salts, alkalis or oxidising agents.

Restoration of blood pressure in acute hypotensive states.

Blood volume depletion should always be corrected as fully as possible before any vasopressor is administered. When, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery ischaemia, Noralin can be administered before and concurrently with blood volume replacement.

Average dosage.

Several strengths are available and, to ensure accurate patient dosage, it is critical to confirm the correct strength and infusion rate have been selected.
Each 1 mL of solution contains 0.06, 0.1, 0.12 or 0.2 mg of noradrenaline (norepinephrine). Give this solution intravenously via a catheter well advanced centrally into the vein and securely fixed, if possible, avoiding a catheter tie-in technique as it promotes stasis.
Administration of Noralin should be controlled by a pump capable of delivering an accurate and consistent volume at a controlled infusion rate in accordance with dosing instructions.
After observing the response to an initial dose of 8 to 12 micrograms of base per minute, adjust the rate of flow to establish and maintain a low normal blood pressure (usually 80 to 100 mmHg systolic) sufficient to maintain the circulation to vital organs. In previously hypertensive patients, it is recommended that the blood pressure should be raised no higher than 40 mmHg below the pre-existing systolic pressure.
The average maintenance dose ranges from 2 to 4 micrograms of base per minute. Great individual variation occurs in the dose required to attain and maintain an adequate blood pressure.
In all cases, dosage of Noralin should be titrated according to the response of the patient. Occasionally much larger daily doses (as high as 68 mg base) may be necessary if the patient remains hypotensive, but occult blood volume depletion should always be suspected and corrected when present.

Duration of therapy.

The infusion should be continued until adequate blood pressure and tissue perfusion are maintained without therapy. The infusion rate should then be reduced gradually avoiding abrupt withdrawal. In some of the reported cases of vascular collapse due to acute myocardial infarction, treatment was required for up to six days.

Adjunctive treatment in cardiac arrest.

Infusions of Noralin are usually administered intravenously during cardiac resuscitation to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means. Noradrenaline's (norepinephrine's) beta-adrenergic stimulating action is also thought to increase the strength and effectiveness of systolic contractions once they occur.

Average dosage.

To maintain systemic blood pressure during the management of cardiac arrest, Noralin is used in the same manner as described under Restoration of blood pressure in acute hypotensive states.

Paediatric use.

Safety and effectiveness in paediatric patients has not been established.

Use in the elderly.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Noralin infusion solutions should not be administered into the veins in the leg in elderly patients.

4.3 Contraindications

Noralin should not be given to patients who are hypotensive from hypovolaemia except as an emergency measure to maintain coronary and cerebral artery perfusion until blood volume replacement therapy can be completed.
If Noralin is continuously administered to maintain blood pressure in the absence of blood volume replacement, the following may occur: severe peripheral and visceral vasoconstriction, decreased renal perfusion and urine output, poor systemic blood flow despite "normal" blood pressure, tissue hypoxia and lactate acidosis.
Noralin should not be given to patients with mesenteric or peripheral vascular thrombosis (because of the risk of increasing ischaemia and extending the area of infarction) unless, in the opinion of the attending physician, the administration of Noralin is necessary as a lifesaving procedure.
Ventricular tachycardia or fibrillation cardiac arrhythmias may result from the use of noradrenaline (norepinephrine) in patients with profound hypoxia or hypercarbia.

4.4 Special Warnings and Precautions for Use

Noradrenaline (norepinephrine) should only be administered by healthcare professionals familiar with its use.
Noralin should be used with extreme caution in patients receiving monoamine oxidase (MAO) inhibitors or antidepressants of the triptyline or imipramine types because severe, prolonged hypertension may result.

Avoid hypertension.

Because of the potency and varying responses to noradrenaline (norepinephrine), the possibility exists that hypertension may be produced with overdoses of this pressor agent. Hence it is desirable to record the blood pressure every two minutes from the time administration is started until the desired blood pressure is obtained, and then every five minutes if administration is to be continued. The rate of flow must be watched constantly, and the patient should not be left unattended whilst receiving Noralin. Headache may be a symptom of hypertension due to overdose.

Hypersensitivity.

Certain patients may be hypersensitive to the effects of noradrenaline (norepinephrine), e.g. patients with hyperthyroidism (see Section 4.8 Adverse Effects (Undesirable Effects)).

Site of infusion.

Noralin should be given into a large vein, particularly an antecubital vein, because when administered into this vein, the risk of necrosis of the overlying skin from prolonged vasoconstriction is apparently very slight. The femoral vein is also an acceptable route of administration. A catheter tie in technique should be avoided if possible, since the obstruction to blood flow around the tubing may cause stasis and increased local concentration of noradrenaline (norepinephrine). As occlusive vascular diseases are more likely to occur in the lower rather than in the upper extremity, the leg veins in elderly patients or in those suffering from such disorders should be avoided. Gangrene has been reported in a lower extremity when infusions of noradrenaline (norepinephrine) were given in an ankle vein.

Extravasation.

The infusion site should be checked frequently for free flow. Care should be taken to avoid extravasation of Noralin into the tissues as local necrosis might ensue due to the vasoconstrictive action of the drug. Blanching along the course of the infused vein, sometimes without obvious extravasation, has been attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This may also progress on rare occasions to superficial slough, particularly during infusion into leg veins in elderly patients or in those suffering from obliterative vascular disease. Hence, if blanching occurs, consideration should be given to changing the infusion site at intervals to allow the effects of local vasoconstriction to subside.
The antidote for extravasation ischaemia is phentolamine. To prevent sloughing and necrosis in areas in which extravasation has occurred, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing 5 mg to 10 mg of phentolamine. Using a syringe with a fine hypodermic needle, the solution is infiltrated liberally throughout the area. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperaemic changes if the area is infiltrated within 12 hours. Therefore, phentolamine should be given as soon as possible after extravasation is noted.

Use in the elderly.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Noralin infusion solutions should not be administered into the veins in the leg in elderly patients.

Paediatric use.

Safety and effectiveness in paediatric patients has not been established.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Noralin infusion solutions should not be mixed with other medicines. Extreme caution should be exercised in patients receiving monoamine oxidase (MAO) inhibitors and antidepressants of the triptyline or imipramine types (see Section 4.4 Special Warnings and Precautions for Use).
Please see Section 6.2 Incompatibilities.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Studies have not been performed.
(Category B3)
Noralin should be given to a pregnant woman only if clearly needed.
Animal studies indicate noradrenaline (norepinephrine) may impair placental perfusion and induce foetal bradycardia. It may also exert a contractile effect on the pregnant uterus and lead to foetal asphyxia in late pregnancy. However, the clinical significance of these changes to a human foetus is unknown. These possible risks to the foetus should therefore be weighed against the potential benefit to the mother.
 It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Noralin is administered to a nursing woman.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Prolonged administration of any potent vasopressor may result in plasma volume depletion which should be continuously corrected by appropriate fluid and electrolyte replacement therapy. If plasma volumes are not corrected, hypotension may recur when Noralin is discontinued, or blood pressure may be maintained at the risk of severe peripheral and visceral vasoconstriction (e.g. decreased renal perfusion) with diminution in blood flow and tissue perfusion with subsequent tissue hypoxia and lactic acidosis and possible ischaemic injury. Gangrene of extremities has been rarely reported. Bradycardia sometimes occurs, probably as a reflex result of a rise in blood pressure. Overdoses or conventional doses in hypersensitive persons (e.g. hyperthyroid patients) cause severe hypertension with violent headache, photophobia, stabbing retrosternal pain, pharyngeal pain, pallor, intense sweating and vomiting.
The following reactions can occur:

Metabolism and nutrition disorders.

Hyperglycaemia, metabolic acidosis due to reduced tissue oxygenation.

Psychiatric disorders.

Insecurity and anxiety, insomnia, confusional state and psychosis, weakness, agitation.

Nervous system disorders.

Headache, tremor.

Eye disorders.

Acute glaucoma (very common in anatomically disposed patients with angle closure).

Cardiac disorders.

Tachycardia, bradycardia (probably a reflex reaction to the increase in blood pressure), arrhythmias, stress cardiomyopathy, palpitations, increased contractility of the heart muscle resulting from the beta-adrenergic effect on the heart (inotropic and chronotropic), acute heart failure, angina pain, myocardial ischaemia, myocardial lesions. An overdose or too-fast intravenous administration may trigger an increase in blood pressure, reflex bradycardia and cardiac arrhythmias, and in extreme cases ventricular fibrillation.

Vascular disorders.

Generalised vasoconstriction, particularly in the skin, mucosa and kidneys with a risk of decreased perfusion of vital organs leading to ischaemia. These effects particularly occur in hypovolaemic patients. Hypertension and tissue hypoxia, ischaemic lesions caused by the potent vasoconstrictor action which may cause cold and pallor of the limbs and face, undue risk of cerebral haemorrhage.

Respiratory, thoracic and mediastinal disorders.

Respiratory failure or shortness of breath, dyspnoea, pulmonary oedema in the event of a substantial increase in blood pressure.

Gastrointestinal disorders.

Hypersalivation, nausea, vomiting.

Skin and subcutaneous tissue disorders.

Pallor, sweating.

Renal and urinary disorders.

Oliguria, anuria, dysuria.

General disorders and administration site conditions.

Ischaemic necrosis at the site of application (e.g. skin), particularly with para or perivascular administration.
Continuous administration of vasopressors to maintain blood pressure without volume expansion may cause the following symptoms: serious peripheral and visceral vasoconstriction; reduced renal blood flow; reduced production of urine; hypoxia; elevated serum lactate concentrations.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdosage with Noralin may result in severe hypertension, reflex bradycardia, marked increase in peripheral resistance and decreased cardiac output. Headache may indicate severe hypertension.
For information on the management of overdose, contact the Poisons Information Centre in Australia on 13 11 26; in New Zealand on 0800 764 766.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Noradrenaline (norepinephrine), a sympathomimetic amine, acts predominantly on α receptors and on β receptors in the heart. It therefore causes peripheral vasoconstriction (α-adrenergic action), and a positive inotropic effect on the heart and dilation of coronary arteries (β-adrenergic action). These actions result in an increase in systemic blood pressure and coronary artery blood flow. In myocardial infarction accompanied by hypotension, noradrenaline (norepinephrine) usually increases aortic blood pressure, coronary artery blood flow, and myocardial oxygenation, thereby helping to limit the area of myocardial ischaemia and infarction. Venous return is increased and the heart tends to resume a more normal rate and rhythm than in the hypotensive state. In hypotension that persists after correction of blood volume deficits, noradrenaline (norepinephrine) helps raise the blood pressure to an optimal level and establish a more adequate circulation.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

No data available.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Noralin contains sodium chloride 8.4 mg/mL (equivalent to 3.3 mg/mL of sodium) for tonicity, hydrochloric acid for pH adjustment, and water for injections.

6.2 Incompatibilities

Infusion solutions containing noradrenaline (norepinephrine) acid tartrate monohydrate have been reported to be incompatible with iron salts, alkalis and oxidising agents, barbiturates, chlorphenamine maleate, chlorothiazide, nitrofurantoin, phenytoin, sodium bicarbonate, sodium iodide, streptomycin sulfate, sulfadiazine and sulfafurazole.
Please see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Do not refrigerate or freeze. Protect from light.

6.5 Nature and Contents of Container

Noralin is supplied in clear glass vials fitted with a rubber stopper and aluminium flip-off cap. It is available in packs of 1 vial.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.


Molecular formula: C8H11NO3.C4H6O6.H2O.
Molecular weight: 337.3 g/mol.
Chemically, noradrenaline (norepinephrine) acid tartrate monohydrate: (1R)-2-Amino-1-(3,4- dihydroxyphenyl)ethanol hydrogen (2R,3R)-2,3-dihydroxybutanedioate monohydrate is a white or almost white crystalline powder. It is freely soluble in water and slightly soluble in ethanol (96%).
Noralin solution for intravenous infusion has a pH of 3.0 to 4.5.

CAS number.

69815-49-2.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Summary Table of Changes